Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the Pfizer Supplemental Savings Plan on May 15, 2024.

Summary

• On May 15, 2024, Albert Bourla, the Chairman and CEO of Pfizer Inc., acquired 18 phantom stock units.
• The acquisition was made through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price of the stock at the time of the transaction was $28.82.
• Following the transaction, Bourla directly owns 668,625 shares.
• The phantom stock units are settled in cash upon Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction indicating the CEO's continued investment in the company, but it's not a major event that would drastically alter investor sentiment.

Positives

• The acquisition of phantom stock units by the CEO demonstrates his continued investment in the company's future.

Industry Context

This filing is a routine disclosure related to executive compensation and holdings, common in publicly traded companies. It provides transparency into the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages often include phantom stock units as a way to incentivize performance and retain key personnel.
• Companies like Johnson & Johnson (JNJ) and Merck (MRK) also utilize similar compensation strategies for their executives.
• The specific number of units and vesting schedules vary based on company size, performance metrics, and industry practices.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and ownership.

Key Dates